SCHEMBL1552035

SCHEMBL1552035

CC(C)(C)OC(=O)N1CCO[C@H](Cc2ccc(OCc3ccccn3)c(Cl)c2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHA2 P29317 4/20 0.46
ERBB2 P04626 3/20 0.46
EPHB4 P54760 1/20 0.46
PDE5A O76074 2/20 0.43
KCNH2 Q12809 1/20 0.42
EGFR P00533 1/20 0.40
ALOX5 P09917 1/20 0.40
ALOX5AP P20292 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
THRB P10828 1/20 0.39
KMO O15229 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1552036 1.00 EPHA2 (0.46) EPHA2ERBB2EPHB4PDE5AKCNH2
SCHEMBL31076359 0.85 EPHA2 (0.51) EPHA2ERBB2EPHB4DRD4
SCHEMBL1552531 0.85 GPR119 (0.46) EPHA2ERBB2EPHB4ALOX5APGPR119
SCHEMBL1552527 0.85 GPR119 (0.46) EPHA2ERBB2EPHB4ALOX5APGPR119
SCHEMBL1553097 0.84 OPRD1 (0.45) EPHA2ERBB2EPHB4DRD4
SCHEMBL1553384 0.83 SMPD1 (0.42) EPHA2ERBB2EPHB4MAPT
SCHEMBL1553330 0.83 SMPD1 (0.42) EPHA2ERBB2EPHB4MAPT
SCHEMBL1552349 0.83 NPC1 (0.49) EPHA2ERBB2EPHB4ALOX5ALOX5AP
SCHEMBL1552562 0.83 GPR119 (0.47) EPHA2ERBB2EPHB4KCNH2GPR119
SCHEMBL1552347 0.83 NPC1 (0.49) EPHA2ERBB2EPHB4ALOX5ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844026-B1 MORPHOLINES AS 5HT2C AGONISTS HOFFMANN LA ROCHE (CH) 2011-04-27 EP disclosed
CN-101107235-B Morpholines as 5HT2C agonists HOFFMANN LA ROCHE 2011-03-16 CN disclosed
US-7323466-B2 Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HOFFMAN-LA ROCHE INC. (US) 2008-01-29 US disclosed
CN-101107235-A Morpholines as 5HT2C agonists HOFFMANN LA ROCHE (CH) 2008-01-16 CN disclosed
US-20060178510-A1 New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HOFFMANN-LA ROCHE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178510-A1 New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HTR2C, HTR1A, HTR1B EPHA2 3530/4885ERBB2 1770/4885EPHB4 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.